PILOT ANTI-CMV CLINICAL TRIAL: PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN HLA-IDENTICAL FAMILIAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH ADVANCED CELLULAR IMMUNOTHERAPY IN PATIENTS WITHOUT SPECIFIC PHARMACOLOGYCAL PROPHYLAXIS AVAILABLE

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520020-28-00

Acronym

INMUNOCELL-CTMV

Enrollment

Registered

2025-01-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus infection post allogeneic allogeneic HLA-identical familial PHT

Brief summary

efficacy is the incidence of CMV infection AT DAY 100 POST-TPH (measured as viral load >200 copies in 2 determinations or >1000 in 1 determination [PCRq]).

Detailed description

Assess the need for CMV treatment, To evaluate the incidence of CMV disease, to assess the presence of allogeneic CMV-specific memory T lymphocytes

Interventions

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
efficacy is the incidence of CMV infection AT DAY 100 POST-TPH (measured as viral load >200 copies in 2 determinations or >1000 in 1 determination [PCRq]).	—

Secondary

Measure	Time frame
Assess the need for CMV treatment, To evaluate the incidence of CMV disease, to assess the presence of allogeneic CMV-specific memory T lymphocytes	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026